Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:24:33 2024-04-19 pm EDT			5-day change	1st Jan Change
1.305 ^USD	-1.14%		-24.85%	+123.48%

02:24pm	Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration	MT
01:13pm	Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy	CI

Ocugen : Thinking about buying stock in Ocugen, aTyr Pharma, Nextplay Technologies, Aerie Pharmaceuticals, or Nutriband?

October 12, 2021 at 08:33 am EDT

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, LIFE, NXTP, AERI, and NTRB.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

OCGN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=OCGN&prnumber=101220211
LIFE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=LIFE&prnumber=101220211
NXTP: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=NXTP&prnumber=101220211
AERI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=AERI&prnumber=101220211
NTRB: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=NTRB&prnumber=101220211

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-ocugen-atyr-pharma-nextplay-technologies-aerie-pharmaceuticals-or-nutriband-301397936.html

SOURCE InvestorsObserver

Latest news about Ocugen, Inc.

Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration	08:24am	MT
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy	07:13am	CI
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	Apr. 10	CI
Ocugen Gets FDA Clearance for IND Amendment for OCU400	Apr. 08	DJ
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial	Apr. 08	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 05	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 05	MT
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise	Apr. 05	MT
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy	Apr. 05	CI
Sector Update: Health Care Stocks Slipping in Afternoon Trading	Apr. 02	MT
Ocugen to Restate Financial Statements; Shares Tumble	Apr. 02	MT
Transcript : Ocugen, Inc., Q4 2023 Earnings Call, Apr 02, 2024	Apr. 02
Ocugen Provides Business Update	Apr. 02	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease	Apr. 01	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 22	MT
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders	Mar. 22	MT
Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director	Mar. 20	CI
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer	Mar. 18	CI
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410	Mar. 13	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ

Chart Ocugen, Inc.

Duration

Period

More charts

Company Profile

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.32 USD

Average target price

6.333 USD

Spread / Average Target

+379.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OCUGEN, INC.	+123.48%	340M
IQVIA HOLDINGS INC.	-2.16%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.26%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.91%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.68%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.65%	11.68B
MEDPACE HOLDINGS, INC.	+20.95%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.79%	11.15B

Other Biotechnology & Medical Research